Country: United States
Language: English
Source: NLM (National Library of Medicine)
Metoclopramide Hydrochloride (UNII: W1792A2RVD) (Metoclopramide - UNII:L4YEB44I46)
General Injectables & Vaccines, Inc.
Metoclopramide Hydrochloride
Metoclopramide 5 mg in 1 mL
INTRAVENOUS
PRESCRIPTION DRUG
Diabetic Gastroparesis (Diabetic Gastric Stasis). Metoclopramide is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The Prevention of Nausea and Vomiting Associated with Emetogenic Cancer Chemotherapy. Metoclopramide Injection, USP is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy. The Prevention of Postoperative Nausea and Vomiting. Metoclopramide Injection, USP is indicated for the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable. Small Bowel Intubation. Metoclopramide Injection, USP may be used to facilitate small bowel intubation in adults and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers. Radiological Examination. Metoclopramide Injection, USP may be used to stimulate gastric emptying and intestinaltransit of barium in cases where delayed emptying interferes with radiological examination of
PRESERVATIVE FREE. Metoclopramide Injection, USP, 5 mg/mL metoclopramide base (present as the monohydrochloride monohydrate) is supplied in the following: Protect from light by retaining in package until time of use.Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] This product is light sensitive. It should be inspected before use and discarded if either color or particulate is observed. Do not store open single-dose vials or ampuls for later use, as they contain no preservative. Discard unused portion. Benadryl is a registered trademark of Warner-Lambert Company. Cogentin is a registered trademark of Merck and Co. Inc Distributed by Hospira, Inc., Lake Forest, IL 60045 USA LAB-1290-1.0 Revised: 5/2018
Abbreviated New Drug Application
General Injectables & Vaccines, Inc. ---------- MEDGUIDE Metoclopramide Hydrochloride, USP You or your caregiver should read the Medication Guide before you start receiving metoclopramide and before you get another dose of metoclopramide. There may be new information. If you take another product that contains metoclopramide, you should read the Medication Guide that comes with that product. some of the information may be different. This Medication Guide does not take the place of talking to your doctor about your medical condition or your treatment. What is the most important information I should know about Metoclopramide? Metoclopramide can cause serious side effects, including: Abnormal muscle movements called tardive dyskinesia (TD). These movements happen mostly in the face muscles. You can not control these movements. They may not go away even after stopping Metoclopramide. There is no treatment for TD, but symptoms may lessen or go away over time after you stop taking Metoclopramide. Your chances for getting TD go up • the longer you take Metoclopramide and the more Metoclopramide you take. You should not take Metoclopramide for more than 12 weeks. • if you are older, especially if you are a woman • if you have diabetes It is not possible for your doctor to know if you will get TD if you take Metoclopramide. Call your doctor right away if you get movements you can not stop or control, such as: • lip smacking, chewing, or puckering up your mouth • frowning or scowling • sticking out your tongue • blinking and moving your eyes •shaking of your arms and legs See the section “What are the possible side effects of Metoclopramide?” for more information about side effects. What is Metoclopramide? Metoclopramide is a prescription medicine used to: • relieve symptoms of slow stomach emptying in people with diabetes • prevent nausea and vomiting that can happen with cancer chemotherapy • prevent nausea and vomiting that may happen after surgery, if your doctor decides that you should not be Read the complete document
METOCLOPRAMIDE- METOCLOPRAMIDE HYDROCHLORIDE INJECTION, SOLUTION GENERAL INJECTABLES & VACCINES, INC. ---------- METOCLOPRAMIDE INJECTION 5MG/ML 2ML SDV WARNING: TARDIVE DYSKINESIA TREATMENT WITH METOCLOPRAMIDE CAN CAUSE TARDIVE DYSKINESIA, A SERIOUS MOVEMENT DISORDER THAT IS OFTEN IRREVERSIBLE. THE RISK OF DEVELOPING TARDIVE DYSKINESIA INCREASES WITH DURATION OF TREATMENT AND TOTAL CUMULATIVE DOSE. METOCLOPRAMIDE THERAPY SHOULD BE DISCONTINUED IN PATIENTS WHO DEVELOP SIGNS OR SYMPTOMS OF TARDIVE DYSKINESIA. THERE IS NO KNOWN TREATMENT FOR TARDIVE DYSKINESIA. IN SOME PATIENTS, SYMPTOMS MAY LESSEN OR RESOLVE AFTER METOCLOPRAMIDE TREATMENT IS STOPPED. TREATMENT WITH METOCLOPRAMIDE FOR LONGER THAN 12 WEEKS SHOULD BE AVOIDED IN ALL BUT RARE CASES WHERE THERAPEUTIC BENEFIT IS THOUGHT TO OUTWEIGH THE RISK OF DEVELOPING TARDIVE DYSKINESIA. (SEE WARNINGS.) DESCRIPTION Metoclopramide hydrochloride is a white or practically white, crystalline, odorless or practically odorless powder. It is very soluble in water, freely soluble in alcohol, sparingly soluble in chloroform, practically insoluble in ether. Chemically it is 4-amino-5-chloro-N- [2-(diethylamino)ethyl]-2-methoxybenzamide monohydrochloride monohydrate. It has the following structural formula: Metoclopramide Injection, USP is a sterile, nonpyrogenic solution of metoclopramide hydrochloride in water for injection. Each milliliter contains metoclopramide base 5 mg (as the hydrochloride monohydrate); 8.5 mg sodium chloride. May contain hydrochloric acid and/or sodium hydroxide for pH adjustment; pH 4.4 (2.5 to 6.5). The solution contains no bacteriostat, antimicrobial agent or added buffer and is intended for use only as a single-dose injection. When smaller doses are required, the unused portion should be discarded. This product is light sensitive. It should be inspected before use and discarded if either color or particulate is observed. Metoclopramide Injection is intended for intravenous or intramuscular administration. CLINICAL PHARMACOLOGY Metoclopramide stimula Read the complete document